Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...
MARLBOROUGH, Mass., Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Boston Scientific just won FDA approval for the first spinal cord neurostimulator system to provide both paresthesia-based and sub-perception therapy at the same time. The WaveWriter system delivers ...
In a recent study of the technology, a total of 90% of patients treated with the WaveWriter technology for three months reported at least a 50% improvement in their pain levels without an increased ...
Boston Scientific Corp. notched another win with the U.S. FDA approval of its spinal cord stimulator (SCS), Wavewriter, for treatment of non-surgical back pain just a week after receiving the agency’s ...
System offers multiple non-drug therapies for people with chronic pain PARIS, Jan. 31, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Spectra ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SCS works by sending electrical impulses to the spinal cord and masking the pain messages travelling to the brain. These electrical impulses can vary in frequency, pulse width and amplitude and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results